165 related articles for article (PubMed ID: 38279087)
21. A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial.
Bhaskaran D; Savage J; Patel A; Collinson F; Mant R; Boele F; Brazil L; Meade S; Buckle P; Lax S; Billingham L; Short SC
BMC Cancer; 2024 Jan; 24(1):83. PubMed ID: 38225549
[TBL] [Abstract][Full Text] [Related]
22. Perampanel: Does it have broad-spectrum potential?
Potschka H; Trinka E
Epilepsia; 2019 Mar; 60 Suppl 1():22-36. PubMed ID: 29953584
[TBL] [Abstract][Full Text] [Related]
23. Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone.
Rascol O; Barone P; Behari M; Emre M; Giladi N; Olanow CW; Ruzicka E; Bibbiani F; Squillacote D; Patten A; Tolosa E
Clin Neuropharmacol; 2012; 35(1):15-20. PubMed ID: 22222634
[TBL] [Abstract][Full Text] [Related]
24. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.
Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Squillacote D; Yang H; Gee M; Zhu J; Laurenza A
Epilepsia; 2013 Jan; 54(1):126-34. PubMed ID: 22905878
[TBL] [Abstract][Full Text] [Related]
25. Perampanel in real-world clinical care of patients with epilepsy: Interim analysis of a phase IV study.
Wheless J; Wechsler RT; Lancman M; Aboumatar S; Patten A; Malhotra M
Epilepsia Open; 2021 Mar; 6(1):79-89. PubMed ID: 33681651
[TBL] [Abstract][Full Text] [Related]
26. Absence of Liver Toxicity in Perampanel-Treated Subjects: Pooled results from partial seizure phase III perampanel clinical studies.
Laurenza A; Yang H; Williams B; Zhou S; Ferry J
Epilepsy Res; 2015 Jul; 113():76-85. PubMed ID: 25986193
[TBL] [Abstract][Full Text] [Related]
27. Efficacy, tolerability and safety of perampanel in population with pharmacoresistant focal seizures: A systematic review and meta-analysis.
Mahajan SS; Prakash A; Sarma P; Niraj N; Bhattacharyya A; Medhi B
Epilepsy Res; 2022 May; 182():106895. PubMed ID: 35305446
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.
Steinhoff BJ; Ben-Menachem E; Ryvlin P; Shorvon S; Kramer L; Satlin A; Squillacote D; Yang H; Zhu J; Laurenza A
Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001
[TBL] [Abstract][Full Text] [Related]
29. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and tolerability of adjunct perampanel based on number of antiepileptic drugs at baseline and baseline predictors of efficacy: A phase III post-hoc analysis.
Glauser T; Laurenza A; Yang H; Williams B; Ma T; Fain R
Epilepsy Res; 2016 Jan; 119():34-40. PubMed ID: 26656783
[TBL] [Abstract][Full Text] [Related]
31. Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: A randomized study evaluating behavior, efficacy, and safety.
Lagae L; Villanueva V; Meador KJ; Bagul M; Laurenza A; Kumar D; Yang H
Epilepsia; 2016 Jul; 57(7):1120-9. PubMed ID: 27221398
[TBL] [Abstract][Full Text] [Related]
32. A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.
Mastall M; Roth P; Bink A; Fischer Maranta A; Läubli H; Hottinger AF; Hundsberger T; Migliorini D; Ochsenbein A; Seystahl K; Imbach L; Hortobagyi T; Held L; Weller M; Wirsching HG
BMC Cancer; 2024 Jan; 24(1):82. PubMed ID: 38225589
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of perampanel in generalized and focal to bilateral tonic-clonic seizures: A comparative study of Asian and non-Asian populations.
Nishida T; Lee SK; Wu T; Tiamkao S; Dash A
Epilepsia; 2019 Mar; 60 Suppl 1():47-59. PubMed ID: 30869168
[TBL] [Abstract][Full Text] [Related]
34. Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures.
Rektor I
Expert Opin Pharmacother; 2013 Feb; 14(2):225-35. PubMed ID: 23259931
[TBL] [Abstract][Full Text] [Related]
35. Study protocol for a phase II randomised, double-blind, placebo-controlled trial of perampanel as an antiepileptogenic treatment following acute stroke.
Nicolo JP; Chen Z; Moffat B; Wright DK; Sinclair B; Glarin R; Neal A; Thijs V; Seneviratne U; Yan B; Cloud G; O'Brien TJ; Kwan P
BMJ Open; 2021 May; 11(5):e043488. PubMed ID: 33972334
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies.
Piña-Garza JE; Rosenfeld W; Saeki K; Villanueva V; Yoshinaga H; Patten A; Williams B; Malhotra M
Epilepsy Behav; 2020 Mar; 104(Pt A):106876. PubMed ID: 31954998
[TBL] [Abstract][Full Text] [Related]
37. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
[TBL] [Abstract][Full Text] [Related]
38. [Perampanel in the treatment of a patient with glioblastoma multiforme without IDH1 mutation and without MGMT promotor methylation].
Rösche J; Piek J; Hildebrandt G; Grossmann A; Kirschstein T; Benecke R
Fortschr Neurol Psychiatr; 2015 May; 83(5):286-9. PubMed ID: 26018396
[TBL] [Abstract][Full Text] [Related]
39. Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial.
Zeyen T; Potthoff AL; Nemeth R; Heiland DH; Burger MC; Steinbach JP; Hau P; Tabatabai G; Glas M; Schlegel U; Grauer O; Krex D; Schnell O; Goldbrunner R; Sabel M; Thon N; Delev D; Clusmann H; Seidel C; Güresir E; Schmid M; Schuss P; Giordano FA; Radbruch A; Becker A; Weller J; Schaub C; Vatter H; Schilling J; Winkler F; Herrlinger U; Schneider M
Trials; 2022 Jan; 23(1):57. PubMed ID: 35045869
[TBL] [Abstract][Full Text] [Related]
40. Sustained seizure freedom with adjunctive perampanel in patients with convulsive seizures: Post hoc analysis of open-label extension studies 307 and 332.
Resnick T; Patten A; Ngo LY; Malhotra M
Epilepsy Behav; 2022 Mar; 128():108528. PubMed ID: 35078116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
